334 related articles for article (PubMed ID: 12438469)
1. The apolipoprotein E epsilon 2 allele and decline in episodic memory.
Wilson RS; Bienias JL; Berry-Kravis E; Evans DA; Bennett DA
J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):672-7. PubMed ID: 12438469
[TBL] [Abstract][Full Text] [Related]
2. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period.
Wilson RS; Schneider JA; Barnes LL; Beckett LA; Aggarwal NT; Cochran EJ; Berry-Kravis E; Bach J; Fox JH; Evans DA; Bennett DA
Arch Neurol; 2002 Jul; 59(7):1154-60. PubMed ID: 12117364
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.
Bennett DA; Wilson RS; Schneider JA; Evans DA; Aggarwal NT; Arnold SE; Cochran EJ; Berry-Kravis E; Bienias JL
Neurology; 2003 Jan; 60(2):246-52. PubMed ID: 12552039
[TBL] [Abstract][Full Text] [Related]
4. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.
Murphy GM; Taylor J; Kraemer HC; Yesavage J; Tinklenberg JR
Am J Psychiatry; 1997 May; 154(5):603-8. PubMed ID: 9137113
[TBL] [Abstract][Full Text] [Related]
5. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
6. [Patterns of cognitive impairment and apolipoprotein genotype in persons with Alzheimer's disease].
Łuczywek E; Pffefer A; Nowicka A; Czyzewski K; ŁaŁowski M; Styczyńska M; Barcikowska M
Neurol Neurochir Pol; 2001; 35(6):1021-33. PubMed ID: 11987699
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease.
Dal Forno G; Rasmusson DX; Brandt J; Carson KA; Brookmeyer R; Troncoso J; Kawas CH
Arch Neurol; 1996 Apr; 53(4):345-50. PubMed ID: 8929157
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
Lasser RA; Dukoff R; Levy J; Levin R; Lehtimäki T; Seubert P; Sunderland T
Int J Geriatr Psychiatry; 1998 Nov; 13(11):767-74. PubMed ID: 9850873
[TBL] [Abstract][Full Text] [Related]
9. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
10. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
Martins CA; Oulhaj A; de Jager CA; Williams JH
Neurology; 2005 Dec; 65(12):1888-93. PubMed ID: 16380608
[TBL] [Abstract][Full Text] [Related]
11. The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults.
O'Hara R; Yesavage JA; Kraemer HC; Mauricio M; Friedman LF; Murphy GM
J Am Geriatr Soc; 1998 Dec; 46(12):1493-8. PubMed ID: 9848808
[TBL] [Abstract][Full Text] [Related]
12. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons.
Boyle PA; Buchman AS; Wilson RS; Kelly JF; Bennett DA
Neuroepidemiology; 2010; 34(1):43-9. PubMed ID: 19907191
[TBL] [Abstract][Full Text] [Related]
13. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults.
Bondi MW; Salmon DP; Monsch AU; Galasko D; Butters N; Klauber MR; Thal LJ; Saitoh T
Neurology; 1995 Dec; 45(12):2203-6. PubMed ID: 8848194
[TBL] [Abstract][Full Text] [Related]
14. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample.
Henderson AS; Easteal S; Jorm AF; Mackinnon AJ; Korten AE; Christensen H; Croft L; Jacomb PA
Lancet; 1995 Nov; 346(8987):1387-90. PubMed ID: 7475820
[TBL] [Abstract][Full Text] [Related]
16. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects.
Engelborghs S; Dermaut B; Goeman J; Saerens J; Mariën P; Pickut BA; Van den Broeck M; Serneels S; Cruts M; Van Broeckhoven C; De Deyn PP
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1148-51. PubMed ID: 12876259
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cognitive decline in old age with brief tests amenable to telephone administration.
Wilson RS; Bennett DA
Neuroepidemiology; 2005; 25(1):19-25. PubMed ID: 15855801
[TBL] [Abstract][Full Text] [Related]
19. Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease.
Levy JA; Bergeson J; Putnam K; Rosen V; Cohen R; Lalonde F; Mirza N; Linker G; Sunderland T
J Int Neuropsychol Soc; 2004 May; 10(3):362-70. PubMed ID: 15147594
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E polymorphism and cognitive impairment in a bi-ethnic community-dwelling elderly sample.
Harwood DG; Barker WW; Ownby RL; Mullan M; Duara R
Alzheimer Dis Assoc Disord; 2002; 16(1):8-14. PubMed ID: 11882744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
